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Abstract. This paper reports on a 71- year-old Caucasian male who underwent neurosurgery for 
an oligodendroglioma, followed by a cranial-sinus fistula and cerebrospinal fluid rhinorrhea. 
The clinical course was complicated due to an extensively drug-resistant Acinetobacter 
baumannii meningitis. The patient was treated with colistin methanesulfonate, intrathecal for 24 
days and intravenous for 46 days. In addition, the patient received meropenem and teicoplanin 
to treat a urinary tract infection and a bacterial aspiration pneumonia. Cerebrospinal fluid 
trough colistin levels resulted above the MIC of A. baumannii. Colistin cerebrospinal fluid 
concentration did not increase over the treatment period. Meningitis was cured and A. 
baumannii eradicated. No side effects from the antimicrobial therapy were observed.  
In conclusion, this case highlights the issues in treating infections caused by resistant Gram 
negative bacteria and supports previous findings on the efficacy, pharmacokinetic and  
tolerability of intravenous and intrathecal colistin treatments. 
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Introduction. Over the last decade, extensively drug- 
resistant Gram-negative bacteria, including 
Acinetobacter baumannii, have become a serious cause 
of hospital-acquired infections. A. baumannii has also 
emerged as a cause of central nervous system (CNS) 
infections, which are often associated with the use of 
external cerebrospinal fluid (CSF) catheters.
1-3
 The 
treatment of these infections can often be extremely 
complex due to antimicrobial resistance and the 
inadequate antimicrobial concentration at the site of 
infection.
1-6
 The increased rate of infections due to 
multi drug-resistant Gram-negative bacteria has been 
reported to lead to a revival in the use of “forgotten” 
antibiotics, such as colistin.
4,5
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Colistin, a polymyxin antibiotic that is administered 
intravenously (IV) as colistin methanesulfonate, is a 
prodrug that is converted in vivo and in vitro into its 
active form colistin.
4,6
 Colistin methanesulfonate and 
colistin poorly cross the brain blood barrier,
4,6
 thus in 
order to treat CNS infections, colistin 
methanesulfonate needs to be administered either 
intrathecally (IT) or intraventricularly (IVT).
3,6
 
The authors report on a case of meningitis caused by 
multi-drug resistant A. baumannii treated with IV and 
IT colistin. 
 
Case Report. A 71-year-old Caucasian male was 
admitted to our hospital with cerebrospinal fluid 
rhinorrhea one month after having undergone 
neurosurgery for an oligodendroglioma. Ten days after 
admission (Table 1), the patient manifested acute 
meningitis caused by methicillin-resistant 
Staphylococcus aureus (MRSA) and Corynebacterium 
striatum, treated with vancomycin IV 750 mg TID and 
imipenem IV 500 mg QD. At the same time, the 
cranial-sinus fistula was repaired. The clinical course 
was complicated by pneumonia and acute respiratory 
insufficiency requiring assisted mechanical ventilation 
(Table 1). A week later, the patient was extubated and 
re-admitted to the floor. The following day, the patient 
manifested a low-grade fever and blood tests evidenced 
increased leukocyte and neutrophil counts; whereas the 
C-reactive protein (C-RP) and erythrocyte 
sedimentation rate (ESR) values were 15.4 mg/dL 
(normal <0.5mg/dL) and 8 mm 1st h (normal 1-30), 
respectively. Due to a persistent drowsiness and a 
suspected hydrocephalus, an external CSF lumbar 
catheter was positioned. The CSF from the catheter 
resulted having normal cell and glucose values, and the 
microbiological investigations were negative. 
Additionally, Enterobacter cloacae urinary infection 
was treated with meropenem (Table 1). Five days later, 
the patient’s temperature rose to 38.8°C, the leukocyte, 
neutrophil, C-RP and ERS values also increased, the 
patient manifested a more depressed level of 
consciousness and the patient complained of neck 
stiffness. Simultaneous CSF findings from the lumbar 
catheter were consistent with acute Gram-negative 
bacterial meningitis.
7
 In addition, the SeptiFast real-
time PCR (SF) (Roche Diagnostics, Monza, Italy)
8
 
performed on the CSF sample from the lumbar catheter 
resulted positive for A. baumannii and K. pneumoniae, 
while the CSF mass spectrometry by matrix-assisted 
laser desorption/ionization time-of-light (MALDI-
TOF) (Bruker Daltonics, Bremen, Germany)
9
 was 
negative. CSF culture yielded A. baumannii and a few 
colonies of K. pneumoniae, both susceptible only to 
colistin. Antimicrobial therapy was administrated : 
intravenous colistin methanesulfonate 4.500.000 
International Unit (IU) (equal to 150 mg of colistin 
based activity) BID (infused over 30’), meropenem 2 g 
TID, rifampin 600 mg OD and teicoplanin 600 mg OD 
after the loading dose plus colistin methanesulfonate IT 
125.000 IU (equal to 4.16 mg of colistin based activity) 
a day.
3,10
 Rifampin had to be discontinued soon after 
due to an allergic reaction. Two days later, after three 
doses of IV colistin and a single dose of IT colistin, a 
repeated culture of CSF, from both the lumbar catheter 
and rachicentesis, evidenced A. baumannii. Whenever  
IT colistin was administered (range of time ± 4h), the 
catheter was kept closed for 3 hours after. CSF samples 
for laboratory investigations and concentrations were 
collected from the lumbar catheter before colistin was 
administered. Colistin concentrations were evaluated 
on samples (stored at -20°C until testing) using an 
HPLC method having fluorimetric detection and 
netilmicin as an internal standard. Linear calibration 
curves were obtained by the concentrations of colistin 
sulfate from 0.30 to 5.0 mg/L in plasma.
11
 On day four 
of therapy, the patient was without fever, CSF cell 
count was decreased, and the culture resulted negative. 
After a total of 24 days of therapy, the lumbar catheter 
was removed, while a lumbar-peritoneal catheter was 
positioned to treat a hydrocephalus that had developed. 
Results of CSF findings are reported in Table 2. IT 
colistin was discontinued while IV colistin, 
meropenem, and teicoplanin were continued for a 
further 22 days, followed by meropenem 3 g and oral 
doxycycline 200 mg per day for another 11 days. 
During this period, the patient was without fever but 
multiple episodes of acute respiratory insufficiency 
occurred, along with alternatively reduced or increased 
neutrophils values, C-RP values, and lung infiltrates. 
Repeated bronchoscopic aspirations were performed, 
and a percutaneous endoscopic gastrostomy (PEG) was 
positioned (Table 1). Repeated respiratory secretion 
cultures evidenced MRSA and K. pneumoniae resistant 
to colistin, but fosfomycin susceptible (Table 1). 
Despite fosfomycin therapy, the patient had a fatal 
episode of acute respiratory insufficiency leading to his 
death.  
 
Discussion. Over the last decade, the frequency of 
CNS infections caused by Gram-negative bacteria has 
increased from 12-27% of cases,
1-3
 as well as 
meningitis caused by A. baumannii.  
In our patient, clinical and microbiological findings 
supported a diagnosis of hospital acquired A. 
baumannii meningitis.
7
 In fact, 1) A. baumannii was 
detected by culture and SF in CSF samples obtained 
from both rachicentesis and the lumbar catheter on the 
third day of treatment; 2) A. baumannii DNA was 
detected by SF (data not shown) in the CSF from day 
12 of treatment; 3) airways were colonized/infected 
with K. pneumoniae, leading us to deduce that the CSF 
could have been contaminated with this microorganism 
during collection.
3,7
 To this regard, it is important to 
report that K. pneumoniae was cultured with A. 
baumannii from the CSF taken on both day one when 
the patient had acute bacterial meningitis and on day 
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Table 1.  Clinical course and microbiological findings. 
Time Diagnosis 
Body 
temperature 
Blood 
WBCs 
X103 (N%) 
CSF 
microbiology 
Respiratory 
secretions 
microbiology 
Invasive 
procedure/s 
Antimicrobial 
therapy 
Day 
10 
Bacterial 
meningitis 
 
38.8°C 8.43 (82%) 
*MRSA+ 
C. striatum 
*MRSA 
Cranial-sinus 
fistula repair 
CSF lumbar 
catheter 
Vancomycin 750 mg 
q8h 
Imipenem 500 mg 
q6h 
Day 
32 
Pneumonia+ 
Respiratory  
insufficiency 
38.0°C 10.7 (87%)  *MRSA 
Assisted 
ventilation 
Linezolid 600 mg 
q12h 
Day  
43 
°UTI+ 
Pneumonia 
37.6°C 9.74 (89%) **Negative 
MRSA+ 
Citrobacter 
koseri+ 
§K. 
pneumoniae 
CSF lumbar 
catheter 
Bronchoscopic 
aspiration 
Linezolid 600 mg 
q12h 
Meropenem 2 g q8h 
Day  
58 
Pneumonia+ 
Bacterial 
meningitis 
38.8°C 9.77 (95%) 
**A. 
baumannii+ 
**K. 
pneumoniae 
 Rachicentesis 
Meropen 2 g q8h 
Teicoplanin 600 mg 
q24h 
Colistin 4.500.000 
IU q12h 
Colistin (IT) 
125.000 IU q24 
Day 
63 
Pneumonia+ 
Bacterial 
meningitis 
<37.0°C 5.90 (69%) Negative   
Meropen 1 g q8h 
Teicoplanin 600 mg 
q24h 
Colistin 4.500.000  
IU q12h  Colistin 
(IT) 125.000 IU q24 
Day 
74 
Pneumonia+ 
Recurrent 
respiratory  
insufficiency 
<37.0°C 4.64 (70%) **Negative 
MRSA+ 
¶K. 
pneumoniae 
Bronchoscopic 
aspiration 
Meropen 1 g q8h 
Teicoplanin 400 mg 
q24h 
Colistin 3.000.000 
IU q12h 
Day 
81 
Clinical 
improvement 
Meningitis 
cured 
<37.0°C 4.96 (73%)  Negative 
CSF lumbar 
catheter 
removed 
CSF lumbar-
peritoneal  
catheter 
positioned 
Meropen 1 g q8h 
Teicoplanin 400 mg 
q24h 
Colistin 3.000.000 
IU q12h 
Day 
94 
Pneumonia+ 
Recurrent 
respiratory  
insufficiency 
<37.0°C 7.87 (78%)  
MRSA+ 
#K. 
pneumoniae 
colistin 
resistant 
Repeated 
bronchoscopic 
aspiration 
Meropenem 1 g q8h 
Doxicicline 100 mg 
q12h (OS) 
Day 
105 
Pneumonia+ 
Recurrent 
respiratory  
insufficiency 
<37.0°C 7.49 (82%)  
#K. 
pneumoniae 
colistin 
resistant 
 
Repeated 
bronchoscopic 
aspiration 
Percutaneous 
gastrostomy 
Meropenem 1g q8h 
Doxicicline 100 mg 
q12h 
Day 
108 
Pneumonia+ 
Recurrent  
respiratory  
insufficiency 
<37.0°C 5.89 (75%)  
#K. 
pneumoniae 
colisitn 
resistant + A. 
baumannii 
multi 
susceptible 
Repeated 
bronchoscopic 
aspiration 
fosfomycin 2g q6h 
# CSF collected from the nose;  *CSF collected from spinal tap; **CSF collected from the lumbar drain; °UTI=Urinary tract infection (pyuria 
and urine culture positive for Enterobacter cloacae; **,§ colistin MIC 0.125 mg/L; ¶colistin MIC >4mg/L; IT= Intratecal, WBCs=white 
blood cells; MRSA=methicillin resistant Staphylococcus aureus. In vitro susceptibility tests were performed with the BD Phoenix automated 
(BD Diagnostic Systems, Sparks, MD), E-test method (bioMerieux, Durham, NC). Break points  for susceptibility were defined according to 
the EUCAST document. 
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Table 2. Cerebrospinal fluid findings 
Date Sample Cells/mm3 
Ratio CSF 
glucose/Blood 
glucose 
Proteins 
mg/dL 
Agar culture Broth culture 
Colistin 
levels mg/L 
23/11 
CSF from  
catheter& 
8100 1/132 361 
^A . baumannii, 
*K. pneumoniae 
(few colonies) 
^A .baumannii, 
*K. pneumoniae 
<0.15 
25/11 
CSF from  
catheter& 
400 8/146 177 A .baumannii 
A .baumannii 
 
2.40 
25/11 
CSF   from 
spinal tap& 
1900 8/146 152 A. baumannii A .baumannii 0.28 
26/11 
CSF from  
catheter 
8560 10/139 187 Negative Negative 7.10§ 
27/11 
CSF from 
catheter 
3000 20/124 253 Negative Negative 0.25§§ 
28/11 
CSF from  
catheter 
172 31/110 180 Negative Negative 6.55 
5/12 
CSF from  
catheter 
64 33/not done 248 Negative Negative 8.40 
10/12 
CSF from 
IT catheter& 
50 45/121 380 Negative 
**K 
.pneumoniae 
1.28 
17/12 
CSF from 
spinal tap 
Absent 50/118 111 Negative Negative  
17/12 Catheter Not applicable Not applicable Not applicable Negative P. aeruginosa  
^ A. baumannii colistin MIC 0.125 mg/L, *K. pneumoniae susceptible to colistin (MIC=0.125 mg/L),  resistant to fosfomycin (MIC≥256 
mg/L), ** K. pneumoniae susceptible to colistin (MIC=1 mg/L) and fosfomycin (MIC ≤16 mg/L), § 0.38mg/L, §§ 2.66mg/L values of 
simultaneous plasma levels, & same  results with the real-time PCR SeptiFast test. CSF samples for microbiologic investigations and  
colistin concentrations were collected from the lumbar catheter before colistin administration, occurring each day with a range of ± 4 h. 
Samples collected for colistin concentrations were immediately stored at -20°C until testing. 
 
17 of treatment when there was clinical improvement 
and CFS laboratory parameters resulted normalized. 
Pseudomonas aeruginosa detected from the lumbar 
catheter was considered of no clinical relevance, given 
an absence of symptoms and CFS abnormalities.
7 
Culture results, SF, and MALDI-TOF tests were 
performed. Microbial culture is still considered the 
reference method for infection diagnosis. SF test is a 
molecular based method used to detect bacteria from 
blood, but it has also been applied to samples different 
from blood.
8
 One of the advantages of SF over culture 
is that the results of this test can be available in less 
than 6 h, allowing for a prompt and more accurate 
empiric therapy. Moreover, SF has a high sensitivity 
for identifying microbial DNA in patients receiving 
antimicrobial therapy.
8
 However, the clinical 
significance of blood microbial DNA, even when 
patients are septic in the absence of microorganism 
growth, is not well defined.
12
 As well, there are limited 
data on the reliability of performing SF on other 
biological samples.
8
 MALDI-TOF is considered a 
reliable, rapid method for identifying bacterial strains 
from colonies on solid culture media
9
 and has also 
been employed to analyze clinical specimens such as 
urine and CSF for direct bacterial identification. 
Nevertheless, for our patient, the best results were 
obtained when the bacterial concentration in the 
sample was ≥105CFU/mL.9 
Colistin is defined as a concentration dependent 
bactericidal antibiotic, therefore, according to Hara GH 
et al., peak levels seem to be more predictive of clinical 
efficacy.
4
 In vitro and in vivo animal studies suggest 
that the area under the curve AUC/MIC and 
Cmax/MIC ratio is the best predictor of antibacterial 
activity. However, the pharmacodynamic parameters 
that best predict efficacy are not well defined.
5,6
 
Overall, it has been suggested to maintain steady state 
levels ≥2 mg/L for effective therapy.5,6 
Considering the in vitro antimicrobial susceptibility 
of A. baumannii isolate and the poor capacity of 
colistin methanesulfonate to cross  the blood brain 
barrier, colistin methanesulfonate was administered 
both intravenously and intrathecally without a loading 
dose.
3,10
 Overall, the treatment resulted being both 
effective and well tolerated.  
In our patient, only trough CSF values were 
obtained, and on 3 different days values below 2 mg/L 
were observed. The ratio between CSF concentration 
and A. baumannii MIC ranged between 2 and 70. This 
broad range could have been due to the different 
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collection times of CSF and/or CSF efflux fluctuations 
through the external drainage.
6
 Overall, the CSF 
colistin concentration did not increase over time, 
mirroring results by Imberti et. al.
6
 Regarding the 
Colistin blood levels without a loading dose, values 
above ≥2 mg/L were registered on day 5 of therapy and 
a lower colistin concentration in the respiratory 
secretions most likely favored the selection of Colistin 
hetero-resistant K. pneumoniae isolates.  
Considering in vitro susceptibility results of K. 
pneumoniae isolates to fosfomycin, it is plausible that 
the variable results reported from our laboratory were 
due to MIC being close to the susceptibility break 
point. When these K. pneumoniae isolates were 
evaluated at a reference laboratory they were reported 
as susceptible to fosfomycin, suggesting that laboratory 
fluctuation could have induced variable susceptibility 
results. Furthermore, PFGE analysis of these isolates 
showed an analogous pattern which was similar to the 
the international blaKPC-3-positive ST258b hybrid 
clone (data not shown).  
It has been suggested that CSF catheters need to be 
removed in order to achieve recovery from a CNS 
infection. However, the exact time of CSF catheter 
removal has yet to be clearly defined.
3,10
 In our case, 
the infection was controlled, and CSF cultures were 
negative after 4 days of treatment, thus, we decided to 
keep the external lumbar catheter in place. It was 
removed only after the meningitis was cured, and a 
lumbar-peritoneal derivation could be placed without a 
high risk of relapse.  
In conclusion, this case highlights the issues 
involved in treating infections caused by drug-resistant 
Gram-negative bacteria and supports previous findings 
on the efficacy, pharmacokinetics and tolerability of 
intravenous and intrathecal Colistin treatments. 
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